The Federal Circuit in its precedential decision in Phigenix v ImmunoGen has ruled the petitioner lacked standing to appeal a Patent Trial and Appeal Board final written decision because of insufficient evidence to show an “injury-in-fact”
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Emily O’Neill, BAT's new head of patents, considers why the first 90 days in a new role are crucial for establishing credibility and understanding your organisation’s culture and objectives